thebench.bio #1 Ecosystem for the Bio-Tech Industry

Clinical Daily Summary

Clinical Daily Summary: What Happened on November 12, 2026

Lilly reports one-year Taltz-Zepbound results in psoriatic arthritis

The trial found higher response and weight-loss rates with the combination. A transplant microbiome analysis missed its primary endpoint, while researchers presented logic-gated cell therapies and Actinium opened enrollment in an imaging study.

  • Updated
  • Read from 4 articles, 3 publications
  • N

Today in brief

Lilly’s 271-person psoriatic arthritis trial found higher rates of disease response and weight loss with Taltz plus Zepbound than with Taltz alone at one year.1 In a transplant analysis, microbiome diversity at engraftment was not significantly linked to one-year non-relapse mortality, but baseline diversity was associated with survival outcomes.2

Lilly reports higher response and weight-loss rates with combination

In the Phase IIIb TOGETHER-PsA trial, 39.2% of participants taking Taltz plus Zepbound had an ACR50 response and lost at least 10% of their body weight by week 52, compared with 1.7% taking Taltz alone.1 ACR50 means at least a 50% improvement in disease signs and symptoms.1

At one year, 43.7% of the combination group had an ACR50 response, compared with 15.7% on Taltz alone. At least 10% weight loss occurred in 85.7% and 6.7%, respectively.1 Minimal disease activity was reached by 28.2% of participants on the combination and 13.6% on Taltz alone.1 These one-year results were exploratory. The trial’s primary endpoint was assessed at week 36.1

Reported adverse events were generally mild or moderate, with no unexpected safety signals reported.1

Transplant analysis misses microbiome primary endpoint

An analysis of 304 transplant participants and 2,575 stool samples found no significant association between microbiome diversity around neutrophil engraftment and non-relapse mortality at one year.2 The analysis missed its primary endpoint. Diversity at engraftment also showed no significant association with the other clinical outcomes examined.2

Participants with lower microbiome diversity at baseline had shorter overall survival and lower graft-versus-host disease-free, relapse-free survival.2 Exploratory analyses found lower microbiome diversity and microbial load 14 to 28 days after transplant in the post-transplant cyclophosphamide group than in the tacrolimus and methotrexate group.2

Also worth knowing

  • At the Society for Immunotherapy of Cancer meeting, at least 10 abstracts described CAR T-cell or T-cell engager designs that use combinations of tumor antigens to control activation. A2 Biotherapeutics said a patient with KRAS G12V-mutant lung cancer remained well 12 months after a complete response to A2B694.3

  • Actinium Pharmaceuticals began enrolling patients with advanced solid tumors in RADIANZ, an imaging study designed to guide development of its HER3-targeting radiotherapy ATNM-400.4

Also published